177167-53-2

Usage

Uses

Used in Organic Synthesis:
2,6-dichloro-4-iodobenzaldehyde is used as an intermediate in organic synthesis for its ability to participate in various chemical reactions, contributing to the formation of complex organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2,6-dichloro-4-iodobenzaldehyde is employed as a key component in the development of new drugs, leveraging its reactivity to create novel pharmaceutical agents.
Used in Agrochemical Development:
2,6-dichloro-4-iodobenzaldehyde also serves as an intermediate in the synthesis of agrochemicals, playing a crucial role in the creation of substances that protect crops and enhance agricultural productivity.
Used as a Reagent:
2,6-dichloro-4-iodobenzaldehyde is utilized as a reagent in the preparation of diverse chemical compounds, facilitating the synthesis process and enabling the production of a wide range of chemical entities.
Safety Considerations:

Upstream product

• 177167-61-2 (2,6-dichloro-4-iodophenyl)methanol 
• 99-99-0 1-methyl-4-nitrobenzene 
• 7149-69-1 1,3-dichloro-2-methyl-5-nitrobenzene 
• 54730-35-7 3,5-dichloro-4-methylaniline 
• 177167-52-1 1,3-dichloro-5-iodo-2-methylbenzene 
• 177167-50-9 5-iodo-2-(bromomethyl)-1,3-dichlorobenzene 
• 177167-51-0 2,6-dichloro-4-iodobenzyl acetate 
• 3032-81-3 3,5-dichloroiodobenzene 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 177167-62-3 2,6-dichloro-4-<(trimethylsilyl)ethynyl>benzaldehyde 

Relevant academic research and scientific papers

Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7)

Here, we report the discovery of a new class of NPBWR1 antagonists identified from a fragment-based screen. Compound 1 (cAMP IC50 = 250 μM; LE = 0.29) emerged as an initial hit. Further optimization of 1 by SAR-by-catalogue and chemical modification produced 21a (cAMP IC50 = 30 nM; LE = 0.39) with a 6700-fold increase in potency from fragment 1. Somewhat surprisingly, Schild analysis of compound 21a suggested that in vitro inhibition of NPW-mediated effects on upon cAMP accumulation were saturable, and that compound 21a dose-dependently increased [125I]-hNPW23 dissociation rate constants from NPBWR1 in kinetic binding studies. Collectively, these data are inconsistent with a classic surmountable, orthosteric mechanism of inhibition. The benzimidazole inhibitors reported herein may therefore represent a mechanistically differentiated class of compounds with which to form a better appreciation of the pharmacology and physiological roles of this central neuropeptide system.

PYRAZOLE AMIDE DERIVATIVE

The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Synthesis of regiospecifically meso-functionalized tetraarylporphyrins via arylbis(2-pyrrolyl)methanes

This paper describes the synthesis of three new porphyrins 1-3 of alternate A2B2 structure, by condensation of arylbis(2-pyrrolyl)methanes and arylaldehydes bearing suitable reactive substituents for further synthetic manipulations. This synthetic approach allows to place the reactive groups selectively on the 5,15 meso-aryls. The new porphyrins feature an ortho-nitro group in the case of 1 and a protected paraethynyl group in compounds 2 and 3. Porphyrin l, after reduction of the nitro group, is a useful intermediate for the preparation of cage or regiospecifically bis-tailed porphyrins. Compounds 2 and 3, after deprotection and Glaser-Hay coupling should give linear polymers (molecular wires) suitable for electron-transfer and light-harvesting processes.